AbbVievsStereotaxis

ABBV and STXS stock compared: price, dividend, valuation and results, from SEC filings.

STXS

Stereotaxis, Inc.

$0.95

Value $92M

+7.95%
STXS's page

AbbVie (ABBV) has a market value of $506B and Stereotaxis (STXS) $92M. Over the last year, with dividends, ABBV moved +25.9% and STXS -55.2%. Dividend yield: ABBV 2.42%, STXS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$506B

    STXS$92M

    ABBV is 5,496 times STXS

  • Revenue, 12 months

    ABBV$66.0B

    STXS$32M

    ABBV is 2,094 times STXS

  • Net income, 12 months

    ABBV$10.3B

    STXS-$22M

  • Operating margin

    ABBV32.2%

    STXS-71.9%

    104.1 points apart

  • ROIC

    ABBV25.7%

    STXS-92.4%

    118.1 points apart

  • P/E

    ABBV49.1

    STXS–

  • Dividend yield

    ABBV2.4%

    STXS0.0%

    2.4 points apart

  • 5-year return

    ABBV+191.4%

    STXS-85.7%

    277.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+191.4%

STXS-85.7%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsSTXSWith dividends
1 year since November 17, 2025+25.9%Price +22.2%-55.2%Price -55.2%
3 years since November 17, 2023+128.7%+31.7% a yearPrice +106.8%-39.1%-15.2% a yearPrice -39.1%
5 years since November 17, 2021+191.4%+23.8% a yearPrice +143.7%-85.7%-32.2% a yearPrice -85.7%
10 years since November 18, 2016+610.5%+21.7% a yearPrice +372.6%+58.3%+4.7% a yearPrice +58.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieSTXSStereotaxis

Valuation

ABBVSTXS
Valuation
Price$286.01$0.95
Market value$506B$92M
Enterprise value (EV)$576B$91M
P/E49.1–
P/E, 5-year median57.0–
P/B–4.3
EV/EBIT27.1–
Free cash flow yield3.7%–

Results and growth

ABBVSTXS
Results and growth
Revenue, 12 months$66.0B$32M
Net income, 12 months$10.3B-$22M
Free cash flow, 12 months$18.9B-$16M
Earnings per share, 12 months$5.81-$0.24
Revenue growth, year on year8.6%20.3%
Revenue growth a year, past+5.9%over 5 years+4.0%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVSTXS
Margins and returns on capital
Gross margin73.7%52.5%
Operating margin32.2%-71.9%
Net margin15.7%-70.9%
ROIC25.7%-92.4%
ROE–-165.0%

Balance sheet

ABBVSTXS
Balance sheet
Cash$10.8B$4.0M
Total debt$80.9B$7.9M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVSTXS
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or STXS

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Stereotaxis?

By market value, AbbVie ($506B) is about 5,496.5 times Stereotaxis ($92M), at today's prices.

How did ABBV and STXS stock do over the last 10 years?

Since November 18, 2016, ABBV's price moved +372.6% and STXS's +58.3%. With dividends: ABBV +610.5% (+21.7% a year), STXS +58.3% (+4.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or STXS?

The dividend yield at today's price is 2.42% for AbbVie and none for Stereotaxis. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Stereotaxis?

Over the last twelve months, the net margin was 15.7% for AbbVie and -70.9% for Stereotaxis, and the operating margin 32.2% and -71.9%. Revenue was $66.0B and $32M.

Which is the better investment, AbbVie or Stereotaxis?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.